| Heading: |
Clinical Trials: Standards |
| Question ID: |
1805202 |
| UIN: |
54197 |
| House: |
Commons |
| Date tabled: |
2025-05-21 |
| Asking Member ID: |
5207 |
| Asking Member display name: |
Clive Jones
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Clive Jones
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps the MHRA is taking to improve (a) transparency and (b) predictability for companies seeking UK Market Authorisations. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) has taken significant steps to improve transparency and predictability for companies seeking United Kingdom market authorisations. This includes clearer guidance, enhanced pre-submission scien... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |